Arthur Levene, MD
Cardiovascular Disease · Littleton, CONPI 1437165784
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,272 of the $14,777 with a category attached, or 69.5%. 34 manufacturers reported payments, led by Novartis at 38.4% of the total. Reporting peaked in 2019 at $6,765 and has fallen 89.6% since, to $705 in 2025. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 249 payments — averaging $59.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$6K
- Impulse Dynamics (USA) Inc.$1K
- Boston Scientific$1K
- AstraZeneca$826
- Abbott$814
- Boehringer Ingelheim$689
- plus $4K from 28 others
What the payments were for
- Speaking & faculty fees$4,48030%
- Travel & lodging$240%
- Food & beverage$10,27270%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 27 | $5,667 |
| Impulse Dynamics (USA) Inc. | 16 | $1,365 |
| Boston Scientific | 14 | $1,148 |
| AstraZeneca | 16 | $826 |
| Abbott | 10 | $814 |
| Boehringer Ingelheim | 17 | $689 |
| Amgen | 37 | $681 |
| E.r. Squibb & Sons, L.L.C. | 22 | $643 |
| Pfizer | 24 | $571 |
| Cvrx, Inc. | 6 | $569 |
| Johnson & Johnson | 15 | $364 |
| Merck | 6 | $237 |
| Heartflow, Inc. | 1 | $169 |
| Akcea Therapeutics, Inc. | 2 | $139 |
| United Therapeutics Corporation | 1 | $125 |
| Kestra Medical Technology Services, Inc. | 3 | $123 |
| Janssen Scientific Affairs, LLC | 1 | $94 |
| Lexicon Pharmaceuticals, Inc. | 5 | $94 |
| Astellas Pharma US Inc | 3 | $45 |
| Scpharmaceuticals Inc. | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 3 | $36 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $36 |
| Portola Pharmaceuticals, LLC | 2 | $35 |
| ZOLL Respicardia, Inc. | 1 | $34 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Edwards Lifesciences | 1 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Bayer | 2 | $23 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Gilead | 1 | $20 |
| Vifor Pharma, Inc. | 1 | $19 |
| GE HealthCare | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$5,084
- OPTIMIZER$994
- Barostim Neo System$500
- JARDIANCE$484
- WATCHMAN Access System$374
- CARDIOMEMS$304
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$249
- VYNDAQEL$245
- LOKELMA$244
- WATCHMAN FLX$169
- FFRct$169
- FARXIGA$133
- TYVASO$125
- RESONATE$125
- TEGSEDI$125
- BRILINTA$123
- Watchman$123
- XARELTO$123
- CAMZYOS$123
- ELIQUIS$122
How this compares
$14,777 in reported general payments places this provider in the 90th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 306 | $460,254 |
| CamzyosMavacamten | 24 | $193,759 |
| EntrestoSacubitril/Valsartan | 32 | $56,047 |
| XareltoRivaroxaban | 46 | $54,718 |
| Repatha SureclickEvolocumab | 44 | $44,877 |
| JardianceEmpagliflozin | 21 | $31,040 |
| FarxigaDapagliflozin Propanediol | 27 | $29,753 |
| SavaysaEdoxaban Tosylate | 15 | $7,171 |
| Atorvastatin Calcium | 467 | $5,168 |
| Metoprolol Succinate | 314 | $4,805 |
| Rosuvastatin Calcium | 275 | $3,127 |
| Ezetimibe | 115 | $3,034 |
| Carvedilol | 270 | $2,743 |
| Spironolactone | 307 | $2,548 |
| Irbesartan | 107 | $2,441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $571 | $460,254306 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $643 | $193,75924 claims |
| NovartisEntresto | $5,667 | $56,04732 claims |
| Johnson & JohnsonXarelto | $364 | $54,71846 claims |
| Boehringer IngelheimJardiance | $689 | $31,04021 claims |
| AstraZenecaFarxiga | $826 | $29,75327 claims |
| Daiichi Sankyo Inc.Savaysa | $20 | $7,17115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Littleton
- Grant BaileyLittleton$88K
- Richard CollinsLittleton$71K
- Josephine Chou CatanzaroLittleton$11K
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- Andrew FreemanDenver$454K
- William SauerAurora$365K
- Jeffrey BooneGreenwood Village$287K
- Rhonda MiyasakaAurora$128K
- Gregory SchwartzAurora$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.